Wedbush analyst Laura Chico raised the firm’s price target on Denali Therapeutics (DNLI) to $31 from $30 and keeps an Outperform rating on the ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback